BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 15448667)

  • 1. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.
    DiGiuseppe JA; Tadmor MD; Pe'er D
    Cytometry B Clin Cytom; 2015; 88(5):294-304. PubMed ID: 25974871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry.
    Tettero JM; Dakappagari N; Heidinga ME; Oussoren-Brockhoff Y; Hanekamp D; Pahuja A; Burns K; Kaur P; Alfonso Z; van der Velden VHJ; Te Marvelde JG; Hobo W; Slomp J; Bachas C; Kelder A; Nguyen K; Cloos J
    Cytometry B Clin Cytom; 2023 Nov; 104(6):426-439. PubMed ID: 37766649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
    Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia.
    Voskova D; Schnittger S; Schoch C; Haferlach T; Kern W
    Leuk Lymphoma; 2007 Jan; 48(1):80-8. PubMed ID: 17325851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aberrant immunophenotypes in 126 patients with acute leukemia].
    He JJ; Li YH; Sun XJ; Wan SG; Xu J; Su L; Tian D
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1032-6. PubMed ID: 17956685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
    Kern W; Voskova D; Schnittger S; Schoch C; Hiddemann W; Haferlach T
    Hematol J; 2004; 5(5):410-8. PubMed ID: 15448667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease.
    Huh YO; Ibrahim S
    Hematol Oncol Clin North Am; 2000 Dec; 14(6):1251-65. PubMed ID: 11147222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease studies by flow cytometry in acute leukemia.
    Campana D; Coustan-Smith E
    Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.